Down-regulation of acyl-CoA oxidase gene expression in heart of troglitazone-treated mice through a mechanism involving chicken ovalbumin upstream promoter transcription factor II.

Cardiac expression of genes involved in fatty acid metabolism may suffer alterations depending on the substrate availability. We studied how troglitazone, an antidiabetic drug that selectively activates peroxisome proliferator-activated receptor gamma (PPARgamma), affected the expression of several of these genes. A single-day troglitazone administration (100 mg/kg/day) did not significantly alter plasma free fatty acids or triglyceride levels. In contrast, a 10-day period of troglitazone treatment significantly reduced plasma free fatty acids and triglyceride levels by 74% (P < 0.001) and 56% (P < 0.01), respectively. Cardiac mRNA expression of acyl-CoA oxidase (ACO) increased (8.3-fold induction) after 1-day troglitazone treatment, whereas after 10 days of treatment ACO mRNA levels were dramatically reduced (98% reduction, P < 0.02), as well as those of uncoupling protein 3 (41% reduction, P = 0.05). The mRNA expression of PPARalpha and several PPAR target genes, such as medium chain acyl-CoA dehydrogenase or fatty acid translocase were not altered after 10 days of troglitazone treatment, whereas muscle-type carnitine palmitoyltransferase I increased 1.7-fold (P < 0.05). The reduction in ACO expression in the hearts of 10-day troglitazone-treated mice was accompanied by an increase in the protein levels of the transcriptional repressor chicken ovalbumin upstream promoter transcription factor II (COUP-TF II). Electrophoretic mobility shift assays performed with COUP-TF II antibody to examine its interaction with a labeled peroxisome proliferator response element probe showed enhanced binding of COUP-TFII in cardiac nuclear extracts from troglitazone-treated mice for 10 days but not in the control nuclear extracts. Overall, the findings presented here show that 10 days of troglitazone treatment decreased expression of the ACO gene through a mechanism involving the transcriptional repressor COUP-TF II.

[1]  H. Uozumi,et al.  Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Inhibition of Cardiac Hypertrophy In Vitro and In Vivo , 2002 .

[2]  Richard T. Lee,et al.  Peroxisome Proliferator-Activated Receptor &ggr; Activators Inhibit Cardiac Hypertrophy in Cardiac Myocytes , 2001, Circulation.

[3]  W. Duckworth,et al.  Insulin inhibits peroxisomal fatty acid oxidation in isolated rat hepatocytes. , 2001, Endocrinology.

[4]  A. Lin,et al.  Activation of NF-κB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. R. Wilson,et al.  Regulation of cardiac and skeletal muscle malonyl-CoA decarboxylase by fatty acids. , 2001, American journal of physiology. Endocrinology and metabolism.

[6]  R. Bergman,et al.  Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity. , 2000, Diabetes.

[7]  M. Alegret,et al.  Down‐regulation of uncoupling protein‐3 and ‐2 by thiazolidinediones in C2C12 myotubes , 2000, FEBS letters.

[8]  I. Komuro,et al.  Peroxisome Proliferator–Activated Receptor Activators Inhibit Lipopolysaccharide-Induced Tumor Necrosis Factor-α Expression in Neonatal Rat Cardiac Myocytes , 2000 .

[9]  T. Ono,et al.  Constitutive Regulation of Cardiac Fatty Acid Metabolism through Peroxisome Proliferator-activated Receptor α Associated with Age-dependent Cardiac Toxicity* , 2000, The Journal of Biological Chemistry.

[10]  D. Kelly,et al.  Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. , 2000, The Journal of clinical investigation.

[11]  K. Petersen,et al.  Mechanism of troglitazone action in type 2 diabetes. , 2000, Diabetes.

[12]  B. McDermott,et al.  Troglitazone does not initiate hypertrophy but can sensitise cardiomyocytes to growth effects of serum. , 2000, European journal of pharmacology.

[13]  Rick B. Vega,et al.  The Coactivator PGC-1 Cooperates with Peroxisome Proliferator-Activated Receptor α in Transcriptional Control of Nuclear Genes Encoding Mitochondrial Fatty Acid Oxidation Enzymes , 2000, Molecular and Cellular Biology.

[14]  D. Ricquier,et al.  The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP. , 2000, The Biochemical journal.

[15]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[16]  J. Lehmann,et al.  A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. , 1999, Diabetes.

[17]  F. Gonzalez,et al.  The role of the peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac lipid metabolism , 1999 .

[18]  S. Walker,et al.  Quantitative RT-PCR : Pitfalls and Potential , 1999 .

[19]  R. Reneman,et al.  Transcriptional regulation of metabolic processes: implications for cardiac metabolism , 1998, Pflügers Archiv.

[20]  D. Kelly,et al.  Fatty Acids Activate Transcription of the Muscle Carnitine Palmitoyltransferase I Gene in Cardiac Myocytes via the Peroxisome Proliferator-activated Receptor α* , 1998, The Journal of Biological Chemistry.

[21]  F. Hegardt,et al.  Control of Human Muscle-type Carnitine Palmitoyltransferase I Gene Transcription by Peroxisome Proliferator-activated Receptor* , 1998, The Journal of Biological Chemistry.

[22]  H. Rockman,et al.  A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[24]  M. Jimenez-Linan,et al.  Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.

[25]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[26]  M. Tsai,et al.  Chick ovalbumin upstream promoter-transcription factors (COUP-TFs): coming of age. , 1997, Endocrine reviews.

[27]  J. Mccormack,et al.  Regulation of energy substrate metabolism in the diabetic heart. , 1997, Cardiovascular research.

[28]  Julio E. Pérez,et al.  Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM , 1997, Diabetes.

[29]  J. McGarry,et al.  The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. , 1997, European journal of biochemistry.

[30]  A. Salminen,et al.  Aging-induced up-regulation of nuclear binding activities of oxidative stress responsive NF-kB transcription factor in mouse cardiac muscle. , 1996, Journal of molecular and cellular cardiology.

[31]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[32]  Eric F. Johnson,et al.  Novel Sequence Determinants in Peroxisome Proliferator Signaling (*) , 1995, The Journal of Biological Chemistry.

[33]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[34]  J. Capone,et al.  Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. McGarry,et al.  Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. , 1989, Diabetes/metabolism reviews.

[36]  H. Taegtmeyer,et al.  Effects of moderate hypertension on cardiac function and metabolism in the rabbit. , 1988, Hypertension.

[37]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[38]  H. Uozumi,et al.  Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. , 2002, Circulation.

[39]  I. Komuro,et al.  Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. , 2000, Circulation research.

[40]  F. Gonzalez,et al.  The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.

[41]  J. Lehmann,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[43]  B. Spiegelman,et al.  15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. , 1995, Cell.